S&P 5007,572.40▲0.4% Nasdaq26,269.23▲0.6% Dow52,658.64▲0.3% Russell 2K2,976.26▲0.4% 10-Yr4.54%−4bp VIX15.67−0.83 WTI$80.18▲1.1% Gold$4,067.10▲0.1% EUR/USD1.147▲0.8% BTC$64,147▼0.9% Nikkei67,744▲0.7%
At close · Wed, Jul 15, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Eli Lilly to buy AtaiBeckley for $2.8 billion

Eli Lilly to buy AtaiBeckley for $2.8 billion

The acquisition is intended to expand Lilly’s pipeline into experimental therapies based on DMT and MDMA.

Reported · Written up by our desk · M&A & Deals

Eli Lilly has agreed to buy psychedelics maker AtaiBeckley in a deal valued at $2.8 billion, according to CNBC Markets.

The transaction is designed to give Lilly access to experimental drug programs built around psychedelics, including treatments based on DMT and MDMA.

CNBC Markets also framed the move as reflecting growing traction for experimental psychedelics therapies as the industry develops clinical momentum.

← Newer storyEurope moves to overhaul banking rules to boost its banks

More like this

US MarketsTSMC pledges another $100bn for Arizona chip plants
US MarketsHyundai Motor explores a deal for SoftBank's Boston Dynamics stake
US MarketsTSMC plans additional $100 billion investment in Arizona after profit jump
US MarketsNextEra and Dominion seek approval for combined power company
US MarketsBerkshire Hathaway stops Gates charity donations after Epstein testimony

Sources

CNBC MarketsEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.